Corvus Pharmaceuticals, Inc. (CRVS) Financial Statements (2025 and earlier)

Company Profile

Business Address 863 MITTEN ROAD
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:41,700,00047,200,00022,100,00027,100,00032,200,00037,000,000
Cash and cash equivalent4,680,00014,841,0007,456,00012,620,00020,105,0007,658,000
Other undisclosed cash, cash equivalents, and short-term investments37,020,00032,359,00014,644,00014,480,00012,095,00029,342,000
Receivables70,00035,00026,00026,00011,000 
Prepaid expense192,000308,00051,000179,000317,000371,000
Other current assets633,000240,000267,000220,000214,000136,000
Other undisclosed current assets326,000475,000407,000431,000352,000403,000
Total current assets:42,921,00048,258,00022,851,00027,956,00033,094,00037,910,000
Noncurrent Assets
Operating lease, right-of-use asset284,000578,000865,0001,149,0001,423,0001,691,000
Property, plant and equipment171,000192,000213,000236,000264,000294,000
Long-term investments and receivables15,187,00015,404,00016,066,00016,123,00017,072,00018,017,000
Long-term investments15,187,00015,404,00016,066,00016,123,00017,072,00018,017,000
Other noncurrent assets252,000129,00089,00089,00089,000129,000
Total noncurrent assets:15,894,00016,303,00017,233,00017,597,00018,848,00020,131,000
TOTAL ASSETS:58,815,00064,561,00040,084,00045,553,00051,942,00058,041,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,186,0002,448,0002,889,0002,518,0002,768,0003,308,000
Accounts payable1,873,0001,213,0001,609,0001,525,0001,404,0002,098,000
Accrued liabilities1,313,0001,235,0001,280,000993,0001,364,0001,210,000
Other undisclosed current liabilities43,220,00010,887,0003,831,0004,351,0004,531,0004,550,000
Total current liabilities:46,406,00013,335,0006,720,0006,869,0007,299,0007,858,000
Noncurrent Liabilities
Liabilities, other than long-term debt    354,000700,000
Operating lease, liability    354,000700,000
Total noncurrent liabilities:    354,000700,000
Total liabilities:46,406,00013,335,0006,720,0006,869,0007,653,0008,558,000
Equity
Equity, attributable to parent, including:12,409,00051,226,00033,364,00038,684,00044,289,00049,483,000
Common stock6,0006,0005,0005,0005,0005,000
Additional paid in capital398,038,000397,255,000375,052,000374,363,000373,791,000372,910,000
Accumulated other comprehensive loss(738,000)(1,355,000)(1,275,000)(967,000)(1,443,000)(1,368,000)
Accumulated deficit(384,897,000)(344,680,000)(340,418,000)(334,717,000)(328,064,000)(322,064,000)
Warrants and rights outstanding  7,118,000    
Other undisclosed equity, attributable to parent  (7,118,000)    
Total equity:12,409,00051,226,00033,364,00038,684,00044,289,00049,483,000
TOTAL LIABILITIES AND EQUITY:58,815,00064,561,00040,084,00045,553,00051,942,00058,041,000

Income Statement (P&L) (USD)

12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
Operating expenses(7,255,000)(5,935,000)(6,253,000)(5,651,000)(5,560,000)(5,622,000)
Other undisclosed operating income     865,0001,284,000
Operating loss:(7,255,000)(5,935,000)(6,253,000)(5,651,000)(5,560,000)(5,622,000)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(32,280,000)2,250,000316,000(3,622,000)  
Loss from continuing operations before equity method investments, income taxes:(39,535,000)(3,685,000)(5,937,000)(9,273,000)(5,560,000)(5,622,000)
Loss from equity method investments(682,000)(577,000)    
Loss from continuing operations:(40,217,000)(4,262,000)(5,937,000)(9,273,000)(5,560,000)(5,622,000)
Other undisclosed net income   236,0002,620,000  
Net loss:(40,217,000)(4,262,000)(5,701,000)(6,653,000)(5,560,000)(5,622,000)
Other undisclosed net loss attributable to parent     (440,000)(881,000)
Net loss available to common stockholders, diluted:(40,217,000)(4,262,000)(5,701,000)(6,653,000)(6,000,000)(6,503,000)

Comprehensive Income (USD)

12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
Net loss:(40,217,000)(4,262,000)(5,701,000)(6,653,000)(5,560,000)(5,622,000)
Comprehensive loss:(40,217,000)(4,262,000)(5,701,000)(6,653,000)(5,560,000)(5,622,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent617,000(80,000)(308,000)476,000(515,000)(1,815,000)
Comprehensive loss, net of tax, attributable to parent:(39,600,000)(4,342,000)(6,009,000)(6,177,000)(6,075,000)(7,437,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: